Forum: Risks and rewards of gene editing
By Marcy Darnovsky,
Issues in Science and Technology
| 07. 31. 2020
In this interview as in past public comments, Jennifer Doudna opens the door to using the CRISPR platform she helped develop in the service of a hugely controversial enterprise: altering the genomes and traits of future children and subsequent generations. She does so under the banner of responsible science and policy. But as with similar comments by supporters of heritable genome manipulations, her responses shed little light on what criteria would constitute “responsible use,” how irresponsible uses could be avoided, and how this immensely consequential decision might be made in an open and democratically responsible way.
To be sure, Doudna notes that “the main challenge in embryo editing is not scientific … but rather ethical,” and raises important questions about the feasibility of consent by future generations, the difficulty of distinguishing between medical applications and enhancements, and the harm that eradicating genetic conditions might bring to people living with those conditions. But she gives no hint about how these challenges could be met. Tellingly, she fails to mention the broader social justice alarms about heritable genome editing: that the accumulation...
Related Articles
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...
By Noah Fromson, HealthLab | 10.19.2026
Gene therapy is no longer the future of medicine — it’s reality. Treatments that replace, silence or edit genes are already changing clinical care.
There are more than 6,000 rare genetic disorders but only a fraction currently have treatable targets...
By Roxanne Khamsi, The Atlantic | 10.16.2026
In recent months, news came out about several distressing cases that have underscored the risks of gene therapy, which delivers DNA to a patient’s cells to treat disease. All of these cases have one thing in common that’s not apparent...
By Rebecca Roberts, The Scientist | 10.11.2026
Heritable genome editing in human embryos is once again under intense scrutiny after the publication of an opinion piece in Trends in Genetics at the end of last month.1 In the paper, Cathy Tie, the founder and chief...